The global Cluster Headache Market is estimated to be valued at US$ 402.12 Mn in 2023 and is expected to exhibit a CAGR of 6.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Cluster headaches are a type of headache disorder characterized by severe pain on one side of the head. The pain generally comes on very quickly and lasts between 15 minutes and 3 hours. Episodes occur at around the same time each day or night during a cluster period. Other symptoms associated with cluster headaches include tearing, a drooping eyelid and nasal congestion on the side of pain. The market comprises drugs for acute treatment and prophylactic treatment of cluster headaches. Some of the commonly prescribed drugs are triptans, corticosteroids, ergots and others. The market is currently driven by strong pipeline with several innovative therapies in late-stage clinical trials which offer improved efficacy and safety over existing options.

Market key trends:
One of the key trends in the cluster headache market is entry of novel treatment options. Some of the companies are developing gene and monoclonal antibody therapies which offer disease modification rather than just acute symptom relief. For instance, Zosano Pharma is developing M207, a novel formulation of zolmitriptan delivered via an investigational wearable drug delivery device for the acute treatment of cluster headaches. Eli Lilly and Company is evaluating an anti-CGRP monoclonal antibody galcanezumab for prevention of cluster headaches. Successful approval and launch of such innovative pipeline therapies will significantly boost the market growth over the forecast period.

Porter’s Analysis
Threat of new entrants: The threat of new entrants is low in the cluster headache market due to high R&D costs associated with developing new drug therapies and treatments. It also requires significant capital to build infrastructure and distribution channels.
Bargaining power of buyers: The bargaining power of buyers is moderate as cluster headaches have a significantly low prevalence and customers have limited treatment options.
Bargaining power of suppliers: The bargaining power of suppliers is moderate due to the presence of a large number of raw material and ingredient suppliers.
Threat of new substitutes: The threat of new substitutes is low as there are limited treatment options available for cluster headaches.
Competitive rivalry: Competition in the cluster headache market is high due to the presence of large pharmaceutical companies.

Key Takeaways
The Global Cluster Headache Market Demand is expected to witness high growth, exhibiting CAGR of 6.4% over the forecast period, due to increasing prevalence of cluster headaches and growing number of treatment options.

Regional analysis
North America dominates the global cluster headache market and is expected to continue its dominance over the forecast period owing to the increasing prevalence of cluster headaches and rising healthcare expenditure. Europe is also among the fast growing regions in the market due to the availability of government funding for treatment of cluster headaches.

Key players
Key players operating in the cluster headache market are Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc.

Read more:

https://insightskies12.blogspot.com/2023/11/acute-and-preventive-treatment-is.html